NCT07376629 2026-01-29
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
Huabo Biopharm Co., Ltd.
Phase 2 Enrolling by invitation
Clinical Trials
3 trialsNCT07310069 2025-12-30
TRANSFORM-GBC
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Enrolling by invitation
NCT06901622 2025-03-30
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Enrolling by invitation